Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
Beth Israel Deaconess Medical Center · Harvard University · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
157
total citations
- FWCI
- 75.30
- Percentile
- 100%
- References
- 35
Citations per year
Authors
20- ABAlexa B. KimballCorresponding
Beth Israel Deaconess Medical Center, Harvard University
- GBGregor B. E. Jemec
Zealand University Hospital, University of Copenhagen
- CJChristopher J. Sayed
University of North Carolina at Chapel Hill
- JSJoslyn S. Kirby
Penn State Milton S. Hershey Medical Center
- EPErrol P. Prens
Erasmus University Rotterdam
Topics & keywords
Topics
Keywords
- Hidradenitis suppurativa
- Medicine
- Double blind
- Placebo
- Clinical trial
- Randomized controlled trial
- Surgery
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.